| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | 0.056 | 0.2 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.052 | 0.2 |
| mRNA | AT13387 | CTRPv2 | pan-cancer | AAC | 0.068 | 0.2 |
| mRNA | AT-406 | CTRPv2 | pan-cancer | AAC | 0.071 | 0.2 |
| mRNA | WAY-362450 | CTRPv2 | pan-cancer | AAC | 0.054 | 0.2 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.066 | 0.2 |
| mRNA | BRD-K19103580 | CTRPv2 | pan-cancer | AAC | 0.053 | 0.2 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | T0901317 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |